Baylor Health Care SystemAbout B

Serving all people by providing personalized health and wellness through exemplary care, education and research.

Research: From moving better to recovering faster, here's what we're studying. 
Need something? Call us: 1.800.4BAYLOR(1.800.422.9567)
Text Size

Research Studies 

Find the trial that interests you in 3 easy steps.

Step 1: Please choose a condition.

Step 2: Select the appropriate diagnosis from the list below. You will then be presented with a listing of the clinical trials taking place at Baylor.

Step 3: Optionally, select a facility.

  • Randomized, Double-Blind, Multicenter, Phase 3 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
  • Safety and Efficacy of Nab®-PACLITAXEL (ABRAXANE®) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (ABOUND.70+)
  • Flight Attendant Medical Research Institute-International Early Lung Cancer Action Project
  • TIGER-2: A Phase 2, Open-Label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-Directed TKI in Patients With Mutant EGFR Non-Small Cell Lung Cancer (NSCLC) With the T790M Resistance Mutation
  • TIGER 1: A Randomized, Open-Label, Phase 2 Study of CO-1686 or Erlotinib as First-Line Treatment of Patients With EGFR-Mutant Advanced NSCLC
  • A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE)
  • A 3-Arm Phase 2 Double-Blind Randomized Study of Carboplatin, Pemetrexed Plus Placebo Versus Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer
  • A Phase 2 Proof-of-Concept Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Non-small Cell Lung Carcinoma
  • Phase III Randomized Study of Standard Versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status